Evidence map›Paper›PMID 40612691›Full record

ArticleJournal of biomed research2024

CRISPR-Cas systems: A revolution in genome editing and its diverse applications.

Joseph Lin, Jun Yang

Abstract read
In one paragraph

Article in Journal of biomed research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Joseph LinDepartment of Internal Medicine, Institute for Human Infections & Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA.
Jun YangDepartment of Internal Medicine, Institute for Human Infections & Immunity, University of Texas Medical Branch, Galveston, TX 77555, USA.

Funding

Epigenetic Mechanism Reprogramming Mucosal Anti-viral Immunity in Allergic AsthmaU01AI136994 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI BRASIER, ALLAN R., CALHOUN, WILLIAM J · 2019 to 2023
$3.4M
Epigenetic Control of Mucosal IRF1/IFN-III Antiviral Response by Enhancer-like Promoter and its Coding lncRNAR21AI159702 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BRASIER, ALLAN R., YANG, JUN · 2021 to 2023
$451k
Silencer-enhancer transition dysregulates interleukin-6 in mucosal epithelial cell plasticityR21AI180682 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI YANG, JUN · 2024 to 2025
$440k
NIAID NIH HHS R21 AI159702NIAID NIH HHS R21 AI180682NIAID NIH HHS U01 AI136994
6 · The paper itself

Abstract

The clustered regularly interspaced short palindromic repeats (CRISPR) Cas (CRISPR6 associated protein) system is an advanced adaptive immune system found in prokaryotes. First discovered in1987, CRISPR Cas has revolutionized genetic research in the past two decades. CRISPR-Cas9 the most widespread system enables precise gene editing by creating double strand breaks. Its ease of use and cost-effectiveness has lowered the barrier to entry for genetic research. CRISPR holds immense potential in many fields from agriculture to medicine. In agriculture, CRISPR has accelerated crop improvement by enabling precise gene edits for desirable traits. In medicine, CRISPR holds promise in xenotransplant, cancers and infectious diseases (HIV) treatment. This review traces the historical development of CRISPR-Cas systems, explores their unique applications, and discusses future advancements aimed at enhancing CRISPR's precision and expanding its applications through technologies like prime and base editing.

Indexed as

Agricultural biotechnologyCRISPR-CasGene TherapyGenome editingXenotransplantation

Identifiers

PMID40612691
PMCPMC12225621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.